Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer
  • Research and Development
  • National Institute of Allergy and Infectious Diseases (UM1AI068614, R01AI34878)

This publication has 23 references indexed in Scilit: